The global Diagnostic Radioisotopes Market is estimated to Propelled by wider applications in medical diagnosis
Diagnostic radioisotopes are radioactive materials used for
medical diagnostic scanning procedures like positron emission tomography (PET)
and single-photon emission computed tomography (SPECT). They are attached to
bioactive molecules specific for disease targets in the body and used to detect
and diagnose diseases like cancer at an early stage. The growing prevalence of
chronic diseases and the need for early and accurate diagnosis is driving the
demand for diagnostic radioisotopes.
The global Diagnostic Radioisotopes Market is estimated to be
valued at US$ 6.54 Bn in 2024 and is expected to exhibit a CAGR of 8.6% over the forecast period 2024-2031, as highlighted in
a new report published by Coherent Market Insights.
Market key trends:
The continued demand for early disease detection therapies is one of the
major trends fueling the diagnostic
radioisotopes market growth. Diagnostic radioisotopes allow detection
of diseases at very early stages, sometimes even before the appearance of
clinical symptoms. This enables timely intervention and improves treatment
outcomes. With growing focus on preventive healthcare, diagnostic radioisotopes
are playing a crucial role in early diagnostics. This increasing demand for
early diagnostics is expected to drive the diagnostic radioisotopes market
during the forecast period.
Segment Analysis
The global diagnostic radioisotopes market is dominated by the cardiology
sub segment which accounts for more than 30% of the overall market share.
Cardiology diagnostics such as Myocardial perfusion imaging helps in precise
identification of coronary artery disease with minimal invasive techniques and
thereby is widely adopted.
Key Takeaways
The global diagnostic radioisotopes market is expected to witness high
growth. The global Diagnostic Radioisotopes Market is estimated to be valued at
US$ 6.54 Bn in 2024 and is expected to exhibit a CAGR of 8.6% over the forecast
period 2024-2031.
Regional analysis related content comprises The North
American region currently dominates the global diagnostic radioisotopes market
with a share of over 35% in 2024. This is attributed to rising prevalence of
chronic diseases, growing geriatric population undergoing diagnostic procedures
in countries like US and Canada. The Asia Pacific region is expected to grow at
the fastest CAGR during the forecast period owing to rising healthcare
expenditure, increasing penetration of molecular diagnostics and nuclear
medicine facilities in populous countries like India and China.
Key players related content comprises Key players operating in the diagnostic
radioisotopes market are Johnson & Johnson, Mueller Sports Medicine, 3M
Company, Andover Healthcare Inc., Medline Industries, Inc. 3M Company has
several collaborations with research institutes for developing new radiotracer
kits to expand its product offerings.
Get
more insights on this topic: https://www.newsstatix.com/diagnostic-radioisotopes-market-share-and-opportunity-analysis/
Comments
Post a Comment